论文部分内容阅读
目的探讨低分子肝素联合银杏达莫治疗急性心源性脑栓塞患者的临床疗效及安全性。方法选取2012年3月至2014年6月东莞市东城医院收治的98例急性心源性脑栓塞患者,将其按随机数字表法分为对照组和观察组,各49例。对照组患者单独采用低分子肝素进行治疗,观察组患者采取低分子肝素联合银杏达莫治疗,比较两组患者临床效果。结果治疗后,观察组患者NIHSS评分明显低于对照组,差异有统计学意义(P<0.05);观察组和对照组患者治疗总有效率、D-Di值、CRP水平、LVEF、LVESD差异均有统计学意义(均P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论在对急性心源性脑栓塞患者的治疗中,采取低分子肝素联合银杏达莫治疗可取得较为显著的效果,能够有效提高患者治疗的总有效率,且不会明显增加不良反应。
Objective To investigate the clinical efficacy and safety of low molecular weight heparin combined with gingko-damo in the treatment of acute cardioembolism. Methods From March 2012 to June 2014, 98 patients with acute cardioembolic infarction admitted to Dongcheng Hospital of Dongguan City were divided into control group and observation group according to random number table method, and each group had 49 cases. Patients in the control group were treated with low molecular weight heparin alone. Patients in the observation group were treated with low molecular weight heparin and ginkgo biloba, and the clinical effects were compared between the two groups. Results After treatment, NIHSS score in observation group was significantly lower than that in control group (P <0.05). The total effective rate, D-Di value, CRP level, LVEF and LVESD in observation group and control group were all significantly lower than those in control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion In the treatment of patients with acute cardioembolism, low molecular weight heparin combined with ginkgo biloba can achieve a more significant effect, which can effectively improve the total effective rate of patients without adverse reactions.